lamotrigine has been researched along with Parkinson Disease, Secondary in 2 studies
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, C | 1 |
| Yan, Z | 1 |
| Zhao, B | 1 |
| Wang, J | 1 |
| Gao, G | 1 |
| Zhu, J | 1 |
| Wang, W | 1 |
| Jones-Humble, SA | 1 |
| Morgan, PF | 1 |
| Cooper, BR | 1 |
2 other studies available for lamotrigine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
D2 dopamine receptors modulate neuronal resonance in subthalamic nucleus and cortical high-voltage spindles through HCN channels.
Topics: Animals; Basal Ganglia; Benzazepines; Brain Chemistry; Cerebral Cortex; Dopamine; Dopamine Antagonis | 2016 |
The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; | 1994 |